Page 1

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement , make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement . Brii Biosciences Breakthrough innovation & insight Brii Biosciences Limited 腾 盛 博 药 生物 科技 有限公司 ( Incorporated in the Cayman Islands with limited liability ) ( Stock Code : 2137 ) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30 , 2026 The Board is pleased to announce the unaudited condensed consolidated interim results of the Group for the six months ended June 30 , 2026 , together with the comparative figures for the previous year , which have been reviewed by the Audit and Risk Committee . FINANCIAL HIGHLIGHTS Our bank deposits and cash and cash equivalents were RMB1,770.8 million as of June 30 , 2026 , representing a decrease of RMB170.2 million or 8.8 % , compared with RMB1,941.0 million as of December 31 , 2025. The decrease was primarily due to payout of research and development activities and daily operations . Other income was RMB19.5 million for the six months ended June 30 , 2026 , representing a decrease of RMB8.6 million or 30.6 % , compared with RMB28.1 million for the six months ended June 30 , 2025. This was mainly due to the decrease in bank interest income of RMB7.9 million attributable to the declining interest rates on time deposits . Research and development expenses were RMB98.3 million for the six months ended June 30 , 2026 , representing a decrease of RMB18.7 million or 16.0 % , compared with RMB117.0 million for the six months ended June 30 , 2025. The decrease was primarily attributable to organizational optimization , compensation framework adjustments and lower third - party contracting costs as Phase 2 study activities for the HBV programs wound down , partially offset by increased investment in early - stage discovery . Administrative expenses were RMB52.6 million for the six months ended June 30 , 2026 , representing a decrease of RMB5.6 million or 9.6 % , compared with RMB58.2 million for the six months ended June 30 , 2025. The decrease primarily reflected lower employee costs following organizational optimization and adjustments to the senior management compensation framework , partially offset by the increase in professional fees and the depreciation and amortization cost . Other gains and losses increased by RMB30.3 million to gains of RMB30.5 million for the six months ended June 30 , 2026 , primarily attributable to the changes in fair value of equity investment . Loss for the period was RMB101.0 million for the six months ended June 30 , 2026 , representing a decrease of RMB47.8 million or 32.1 % , compared with RMB148.8 million for the six months ended June 30 , 2025. The decrease in loss was primarily attributable to the increase in other gains , as well as the decrease in operating expenses . 1